Pancreatic Cancer Research

ResearcherState Key Laboratory of Oncology in South ChinaActive in the last 2 years

Xiaofeng Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3098-5184; OpenAlex author ID A5061756846. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Correction: circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-026-02730-6↗
  2. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Co-author DOI 10.1186/s12943-020-01196-4↗
  3. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01205-6↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhao Chen · 3 shared papers, 2020–2026 · strength 0.50
  2. Zhihua Li · 3 shared papers, 2020–2026 · strength 0.50
  3. Yao Kong · 3 shared papers, 2020–2026 · strength 0.50
  4. Yuming Luo · 3 shared papers, 2020–2026 · strength 0.50
  5. Y P. Li · 1 shared paper, 2026 · strength 0.29
  6. Rufu Chen · 1 shared paper, 2026 · strength 0.29
  7. Rufu Chen · 2 shared papers, 2020 · strength 0.21
  8. Zhiqiang Fu · 1 shared paper, 2020 · strength 0.10
  9. Leyi Huang · 1 shared paper, 2020 · strength 0.10
  10. Quanbo Zhou · 1 shared paper, 2020 · strength 0.10
  11. Zhiguo Li · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.